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We describe the characterization of the herpes simplex virus type 2 (HSV-2) gene encoding infected cell
protein 32 (ICP32) and virion protein 19c (VP19c). We also demonstrate that the HSV-1 UL38/ORF.553 open
reading frame (ORF), which has been shown to specify a viral protein essential for capsid formation (B.
Pertuiset, M. Boccara, J. Cebrian, N. Berthelot, S. Chousterman, F. Puvian-Dutilleul, J. Sisman, and P.
Sheldrick, J. Virol. 63:2169-2179, 1989), must encode the cognate HSV type 1 (HSV-1) ICP32/VP19c protein.
The region of the HSV-2 genome deduced to contain the gene specifying ICP32/VP19c was isolated and
subcloned, and the nucleotide sequence of 2,158 base pairs of HSV-2 DNA mapping immediately upstream of
the gene encoding the large subunit of the viral ribonucleotide reductase was determined. This region of the
HSV-2 genome contains a large ORF capable of encoding two related 50,538- and 49,472-molecular-weight
polypeptides. Direct evidence that this ORF encodes HSV-2 ICP32/VP19c was provided by immunoblotting
experiments that utilized antisera directed against synthetic oligopeptides corresponding to internal portions of
the predicted polypeptides encoded by the HSV-2 ORF or antisera directed against a TrpE/HSV-2 ORF fusion
protein. The type-common immunoreactivity of the two antisera and comparison of the primary amino acid
sequences of the predicted products of the HSV-2 ORF and the equivalent genomic region of HSV-1 provided
evidence that the HSV-1 UL38 ORF encodes the HSV-1 ICP32/VP19c. Analysis of the expression of the HSV-1
and HSV-2 ICP32/VP19c cognate proteins indicated that there may be differences in their modes of synthesis.
Comparison of the predicted structure of the HSV-2 ICP32/VP19c protein with the structures of related
proteins encoded by other herpesviruses suggested that the internal capsid architecture of the herpes family of
viruses varies substantially.
The herpes simplex viruses type 1 (HSV-1) and type 2
(HSV-2) are closely related with respect to virus structure,
biochemistry, and biology (62). The virion morphologies of
the viruses are virtually indistinguishable (70). The genetic
arrangement of the two viral genomes is colinear for the
most part, and the viruses display significant nucleotide
sequence identity (>50%) (40, 62). Comparisons of the
primary amino acid sequences of analogous HSV-1 and
HSV-2 proteins predicted from DNA sequence analyses
have demonstrated that the structures of many cognate
proteins are conserved to a great extent (11, 26, 37, 74). The
HSVs share some similar biological properties including the
ability to establish and reactivate from latent infection in
neural tissues of the infected host, a broad host range in
cultured cells, and a number of features of viral pathogenesis
(62). However, the viruses differ with respect to the partic-
ulars of viral gene regulation (32, 56), the structures of
specific genes and proteins (47, 48, 52, 63), their abilities to
transform cells in culture (60), and their pathogenic potential
in certain hosts and tissues (16).
The complete nucleotide (nt) sequence of one HSV-1
isolate (strain 17) has been determined (51). This virus has a
genome of 152,260 nt which contains at least 72 probable
protein-encoding open reading frames (ORFs). Additional
ORFs have been identified in other HSV-1 strains (12, 78),
and more are likely to be discovered. Still, it is probable that
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the total number of ORFs discerned will remain in general
agreement with reported estimates of less than 100 viral
proteins specified in infected cells (62). The viral proteins
encoded by many of the HSV-1 ORFs have been identified,
and their basic roles in the coordinately regulated ot, 3, -y
cascade of viral gene expression have been determined
(33-35, 51). This is particularly true of the viral ot trans-
acting proteins and of the viral a proteins that are involved in
viral DNA replication and nt pool synthesis. However, many
of the viral -y structural proteins have yet to be assigned to
specific genes, and their roles in virion assembly or structure
remain to be elucidated (62).
One such protein, infected cell protein 32 (ICP32), has
been shown to correspond to virion protein 19c (VP19c) (8).
This identification was based on characteristic differences in
electrophoretic mobilities between the HSV-1 and HSV-2
ICP32/VP19c proteins and on the extremely tight genetic
cosegregation of ICP32 and VP19c in studies of HSV-
1/HSV-2 intertypic recombinants (4, 41). These genetic
studies mapped the HSV-1 and HSV-2 ICP32/VP19c genes
to a region of the viral genome very close to the gene
encoding ICP6, the large subunit of the viral ribonucleotide
reductase.
VP19c is a component of type A capsids, but the role of
the protein in capsid structure or assembly is currently
unclear (25, 28, 66). Type A capsids are found predominantly
in the nucleus and have also been termed empty capsids
because their centers are electron translucent and thus
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FIG. 1. (A) Position on the HSV-2 (G) genome of the DNA sequenced in this study. (B) Map locations of relevant restriction endonuclease
sites. The BamHI E fragment which maps from approximately 0.533 to 0.583 HSV-2 map units was subcloned as three SstI fragments and
two PstI fragments. (C) Map position of the 2,104-base-pair (bp) region of HSV-2 DNA sequenced in these studies and its relation to published
HSV-2 DNA sequences (74). (D) Location of the HSV-2 large ORF shown in this study to encode ICP32/VP19c is depicted relative to the
gene encoding the large subunit of the viral ribonucleotide reductase (74).
appear to lack any internal core structure (25, 67). In
addition to VP19c, type A capsids also contain four other
proteins, VP5, VP23, VP24, and a small 12-kilodalton (kDa)
protein (15, 17, 25, 27). VP5 composes the hexameric
capsomers and appears to be linked to VP19c by a disulfide
bond (19, 22, 73, 83). VP23 is exposed to the exterior of the
virion and probably serves to connect the hexameric cap-
somers to one another (9). VP24 and the small 12-kDa
protein have been assigned to the capsid interior, but their
structural roles in the capsid remain obscure (9, 66). One
report suggested that VP19c composes the 12 pentameric
capsomers of the viral capsid (77). However, other reports
have adduced VP19c to be an internal capsid protein (8, 9,
25, 67). One clue to the function of VP19c may lie in the
observation that the HSV-1 and HSV-2 ICP32/VP19c pro-
teins (after denaturation and partial renaturation) have a
strong affinity for DNA (8). Whether this property of the
ICP32/VP19c molecule(s) reflects the structural role of the
protein(s) in the capsid or is functionally important to the
processes of capsid assembly or viral DNA packaging re-
mains to be determined.
Recently, Pertuiset et al. (58) reported on the physical
mapping and nt sequence of an HSV-1 gene essential for
capsid assembly. These investigators observed that a muta-
tion in an ORF mapping from 0.553 to 0.565 HSV-1 map
units (ORF.553), corresponding to the HSV-1 (strain 17)
UL38 ORF, affects capsid assembly in a temperature-sensi-
tive manner. However, the protein encoded by ORF.553 was
not identified in these studies, which made it difficult for the
authors to postulate a role for the ORF.553 gene product in
capsid morphogenesis.
In this account, we report the nt sequence of a large ORF
present in the HSV-2 genome that corresponds to the HSV-1
ORF.553 and UL38 ORFs. We demonstrate that this HSV-2
ORF encodes ICP32/VP19c, and we provide evidence that
the cognate HSV-1 ICP32/VP19c molecule is the protein
essential for capsid formation that is encoded by the UL38/
ORF.533 HSV-1 ORF. In addition, the data demonstrate
that there are type-specific differences in the regulation or
processing or both of the HSV-1 and HSV-2 ICP32/VP19c
molecule(s). The results of these studies resolve the location
of the gene encoding ICP32/VP19c on the viral genome and
provide detailed molecular information on which to base
future studies of the structural and functional roles of
ICP32/VP19c in capsid assembly and virion morphogenesis.
MATERIALS AND METHODS
Viruses and cells. The origin and properties of the HSV-1
(Justin) and HSV-2 (G) isolates used in these studies have
been described previously (20, 21). Virus stocks were pre-
pared and their titers were determined on HEp-2 cells (64).
Crude cell lysates were prepared by infecting HEp-2 cells
with 5 to 10 PFU per cell, and cultures were incubated at
37-C (5, 56).
DNA sequencing. The 7.4-kilobase (kb) BamHI E frag-
ment, map coordinates 0.553 to 0.583, of HSV-2 (G) DNA
isolated from virions was cloned into pUC19 for DNA
sequencing (57) (Fig. 1). Three SstI fragments of 2, 1, and 0.3
kb and two PstI fragments of 2.4 and 1.4 kb were subcloned
into the polylinker region of M13mp2O and M13mp2l (Inter-
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national Biotechnologies, Inc., New Haven, Conn.). Single-
stranded and replicative-form DNAs were prepared as de-
scribed previously (54).
Both strands of the HSV-2 DNA inserts were sequenced
by the dideoxy-chain termination method (65). The first
sequencing reactions were done with the M13 universal
primer (International Biotechnologies). Subsequent reac-
tions were done with custom primers (17 nt) derived from
sequence generated in previous sequencing experiments.
The oligonucleotide primers, all purified by high-pressure
liquid chromatography, were purchased from Operon Tech-
nologies, Inc. (Alamita, Calif.). Both strands of all HSV-2
DNA inserts were completely sequenced, and computer
methods were used to compile and analyze the data.
In initial experiments, considerable difficulty was experi-
enced in obtaining readable sequence. This was because the
secondary structures which formed in the G+C-rich DNA
resulted in blocks to the Klenow polymerase as well as in
compressions in the gel. Improved results were obtained
with deoxy-7-deaza-GTP (Boehringer Mannheim Biochemi-
cals, Indianapolis, Ind.) in place of dGTP (55) and strongly
denaturing gels (7 M urea, 40% formamide) (49). The best
results were obtained by using dIPT in place of dGTP (75),
Escherichia coli single-stranded-DNA-binding protein (10),
and Sequenase (modified bacteriophage T4 DNA polymer-
ase) (United States Biochemical Corp., Cleveland, Ohio). It
was not necessary to use formamide in the gels with the
latter method. [35S]dATP (Dupont, NEN Research Prod-
ucts, Boston, Mass.) was used as the radioactive label. The
gels were fixed in 12% acetic acid-10% methanol, dried, and
autoradiographed for approximately 15 h (7).
Generation of antipeptide antisera. The choice of oligopep-
tides was based on regions of amino acid identity conserved
between the predicted primary amino acid sequence en-
coded by the HSV-2 ICP32/VP19c ORF and the predicted
polypeptide product of the varicella-zoster virus type 20
(VZV-20) ORF (18). Predicted regional hydropathicity and
structural mobility were also considered (13, 14, 36, 45, 61).
Oligopeptides (12 to 15 amino acids long) were obtained from
Biosearch (Palo Alto, Calif.). Peptides were coupled to
keyhole limpet hemocyanin, and antisera were prepared
essentially as described previously (1). Three rabbits were
immunized for each peptide, and hyperimmune antisera
were obtained (three bleedings per rabbit).
Preparation of 58,700-kDa TrpE fusion protein and gener-
ation of antiserum. The pATH10 plasmid was obtained from
T. J. Koerner. This plasmid makes a 37,000-molecular-
weight fragment of the TrpE protein under control of the trp
promoter. The 1.4-kb PstI fragment of HSV-2 DNA (Fig. 1)
was ligated into the PstI site at the 3' end of the trp gene in
pATH10 to produce a fusion gene and cloned by transfor-
mation of E. coli RR1 cells. The fusion protein synthesized
by this recombinant clone should have 197 amino acids of
the HSV-2 protein (amino acids 260 to 466) and a molecular
weight of 58,700. The fusion protein was induced with 20 ,ug
of 3-,-indoleacrylic acid (Sigma Chemical Co., St. Louis,
Mo.) per ml and separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). The fusion
protein band was excised from the SDS-polyacrylamide gel,
and 25 to 50 ,ug of purified protein was used to immunize
rabbits (76).
PAA inhibition of viral DNA synthesis. Cells were treated
with phosphonoacetic acid (PAA) at a concentration of 300
,ug/ml of culture medium 4 h before infection, and this level
was maintained throughout infection (82).
Radiolabeling of proteins and SDS-PAGE. Mock- and vi-
rus-infected cultures were radiolabeled with [35S]methionine
(>1,000 Ci/mmol; Dupont) at 20,uCi/ml in methionine-free
medium. Polypeptides in cell lysates were electrophoreti-
cally separated on a 9.25% N,N'-diallyltartardiamide-cross-
linked SDS-polyacrylamide gel (56).
Immunoblotting. Polypeptides separated by SDS-PAGE
were electrophoretically transferred to nitrocellulose mem-
branes (8). For autoradiography, blots were dried at 37°C for
several hours before being exposed to Kodak XRP1 X-ray
film at -70°C. For immunoblotting, membrane filters were
blocked by incubation for 2 h in phosphate-buffered saline
containing 3% nonfat milk powder and then reacted with
rabbit antipeptide serum diluted in phosphate-buffered saline
containing 1% gelatin for 2 to 12 h at room temperature.
After being washed with phosphate-buffered saline contain-
ing 0.05% Tween 20, blots were reacted with biotin-conju-
gated goat anti-rabbit immunoglobulin G for 1 to 2 h at 'room
temperature, followed by incubation for 30 min at room
temperature with avidin-peroxidase complex (VectaStain;
Vector Laboratories). Bound antibody was visualized by
developing in horseradish peroxidase color development
substrate solution (Bio-Rad Laboratories, Richmond, Cal-
if.).
Computer analysis. Alignment of the predicted primary
amino acid sequence of the HSV-2 ICP32/VP19c polypeptide
employed several protein alignment programs (46, 72, 81),
and minor adjustments were done by hand. The alignment of
the predicted product of the Epstein-Barr virus (EBV)
BORFi ORF in regions that showed little homology with the
other predicted proteins was arbitrarily biased toward max-
imizing conservative substitutions with little consideration
of gap penalties. Protein hydropathicity indexes were pre-
dicted by the algorithms of Hopp and Woods (36) and Kyte
and Doolittle (45).
RESULTS
DNA sequence analysis. To determine the nucleotide se-
quence of the portion of HSV-2 DNA deduced to encode the
ICP32/VP19c protein, we sequenced the region of the viral
genome mapping from approximately 0.553 to 0.565. SstI
and PstI subfragments of the BamHI E fragment were
cloned into appropriate M13 vectors, and primer walking
techniques were used to determine the DNA sequence. The
organization of the region of the viral genome sequenced,
including locations of pertinent restriction endonuclease
sites, orientation with respect to previously published HSV-
2 DNA sequences, and the provenance of the DNA se-
quences encoding the ICP32/VP19c and ICP6 (large subunit
of ribonucleotide reductase) proteins is illustrated in Fig. 1.
The nucleotide sequence of the noncoding strand of the
HSV-2 ICP32/VP19c gene is shown in Fig. 2. Only one
1,222-base-pair ORF (from nt 541 to 1938) large enough to
encode ICP32/VP19c was identified in the sequenced region.
This ORF contains two ATG codons located near the 5' end,
at nt 541 and 571, which could serve as translation start sites
(42-44), and the ORF extends to the TGA stop codon
beginning at nt 1939. Translation initiation and termination at
these codons would result in polypeptides of 50,538 and
49,472 Da, both of which are in close agreement to previous
size estimates for HSV-2 ICP32/VP19c (56). The predicted
sequence of the larger polypeptide is shown in Fig. 2. The
DNA sequences 5' to the ORF contain several possible
transcriptional regulatory elements. These are elucidated in
the Discussion and are illustrated in Fig. 5. The consensus
polyadenylation signals AATAAA and TGTGTTG (53, 59)
appear in the sequence 121 and 150 nt 3' to the ORF.
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TTTAAACATTTGCGTATGCACCGGCCCAGCCAGTCGGACACCGGAACCCACCAGAGGCGGAAGCCGCCTTCGCCCGTGAGGGTGCGTGT
GTTTTCTGGTGGCGTGTTTTTCCTTTCCGCCCTCCTCCCTCCCCACCQCCACCACCCCCCACTCGCCCGTTGGCGATCGGCGGGAAAACCQTGAAAACCAAGCCQCTCCCGACAGCCCCG
MetLysThrLysProLeuProThrAlaPro
*Sst I
ATGGCGTGGGCCGAGAGTGCCGTGGAAAC CACCCCGGCCCGCGCGAGCTCGCGGGCCQACGCCCCGCTCCGGCGCGTCCTGCGCCCGCCCQATCGCTCGCCGCGACGGCCCGGTGCTTTTG
MetAlaTrpAlaGluSerAlavalGluThrThrThrGlyProArgGluLeuAlaGlyHisAlaProLeuArgArgValLeuArgProProIleAlaArgArgAspGlyProValLeuLeu
GGGGACAGGGCCCCCQGGAGGACGGCCQGTACGATGTGGCTGCTGGGGATCGACCCCGCGGAGTCGTCTCCGGGAACGCGCGCTACCCGAGACGATACCGAGCAGGCCGTGGACAAGATC
GlyAspArgAlaProArgArgThrAlaSerThrMetTrpLeuLeuGlyIleAspProAlaGluSerSerProGlyThrArgAlaThrArgAspAspThrGluGlnAlaValAspLysIle
CTCAGGGGAGCCCGGCGCGCGGGAGGGCTGACCGTCCCCGGCGCCCCCCGCTATCACCTGACCCGCCQGGTAACCCTGACGGATCTCTGCCAACCAAACGCGGAGCGGGCCGGGGCGCTC
ATCACGACCAACTACGGCGGGACGCGGGCCGGGGCGCGGCTGGACCGGTTTTCCGAATGCCTGCGCGCCQTGGTCCQQCGCACGTGTTTCCCCACGAGGTCATGCGGTTTTTCGGGGGG
IleThrThrAsnTyrGlyGlyThrArgAlaGlyAlaArgLeuAspArgPh S-rGluCyaLeuArgAlaMetValHisThrHisValPheProHisGIuValMetArgPhePheGlyGly
*Pat I
CTAGTGTCGTGGGTCACACGGACGAGCTGGCTAGCGTCACCGCCGTCTGCAGCGGACCCCAGGAGGCCQQQQCCCGGCCQCCCGGGCAGGCCCCGTTCGGCCGTTACCQTCCCGGCC
LeuValSerTrpValThrGlnAspGluLouAlaSerValThrAlaValCyaSerGlyProGlnGluAlaThrHisThrGlyHisProGlyArgProArgSerAlaValThrIleProAla
* Sat I
TGCGCCTTCGTGGACCTGGACGCCGAGCTGTGCCTGGGGGGCCCTGGGGCGGCGTTCCTGTACTTGGTCTTQACCTACCGACAGTGCCGGGACCQGGAGCTCTGTTGCGTGTACGTGGTC
CysAlaPheValAspLeuAspAlaGluLeuCyaLeuGlyGlyProGlyAlaAlaPh ILeuTyrLeuValPheThrTyrArgGlnCysArgAspGlnGluLeuCysCysValTyrValVal
AAGAGCCAGCTCCCCCCGCGCGGACTGGAGGCGGCCCTCGAGCGGCTGTTCGGGCGCCTCCGGATAACCAACACGATTQACGGGGCCGAGGACATGACGCCCCCTCCCCCGAACCGAAAC
LysSerGlnLeuProProArgGlyLeuGluAlaAlaLeuGluArgLeuPheGlyArgLeuArgIleThrAsnThrIleHiaGlyAlaGluA3pMetThrProProProProAsnArgAsn
*Sst I
GTTGACTTTCCGCTCGCCGTCCTGGCCGCGAGCTCGCAATCCCCGCGGTGCTCGGCGAGCCAAGTCACGAACCCCCAGTTTGTCGACAGGCTGTACCGCTGGCAGCCGGATCTGCGGGGG
ATCCTGGAGGGCGTGGTGTGGCGCCCCGGCGGGTGGCGGGCCTGCGCGTGATCGTCTATTGACGACGGCCGCCCAACCCGAGCGACCTTCTCCTCCCACTTTCCCCCCCCCTCCTACACA
IleLeuGluGlyValValTrpArgProGlyGlyTrpArgAlaCysAla
CCAACTCCGCCCTCGCCGTCTTGGCCGTGCGCGGCCCCGTGCGTCCGTCTCAATAAAGCCAGGTTAAATCCGTGACGTGGTGTGTTTGGCGTCTCTCTCTGAAATGSCGGAAACCGACATI---> Swfain and Galloway --->
GCAAATGGGATTCATGGACACGTTACAC
FIG. 2. Nucleotide sequence of the HSV-2 ICP32/VP19c gene. The nucleotide sequence of the ORF is depicted. The amino acid sequence
of the predicted polypeptide is presented starting at the first ATG, which represents the first of two possible translation initiation sites (see
text). The DNA sequence presented in this figure begins with the probable TATA box which occurs at nucleotide position 361 of the
2,158-base-pair sequence determined in this study. HSV-2 DNA sequences 5' to this position are presented in Fig. 5. The consensus
polyadenylation signals AATAAA and TGTGTTG associated with the ORF are underlined. The locations of the SstI and PstI restriction sites
are indicated by asterisks (*).
Identification of ICP32/VP19c as the product of the HSV-2
ORF. (i) Immunoblotting experiments. The polypeptide prod-
uct of the HSV-2 ORF was identified as ICP32/VP19c by
immunoblotting experiments. These experiments (Fig. 3 and
4) utilized two types of antisera: (i) antisera directed against
synthetic oligopeptides corresponding to portions of the
predicted 50,538-molecular-weight polypeptide encoded by
the ORF, and (ii) antisera directed against a TrpE/HSV-2
ORF fusion protein overexpressed and isolated from E. coli.
Synthetic oligopeptides corresponding to regions of the
predicted polypeptide encoded by the HSV-2 ORF that
share sequence or structural identity with the predicted
product of the VZV 20 ORF were synthesized and used to
raise antisera in rabbits. The peptides synthesized and their
locations in the predicted molecule were as follows:
LTRQVTLTDLCQPNA (number 1), residues 110 to 124;
ERAGALLLALRHPTD (number 2), residues 125 to 139;
and TAVCSGPQEATHT (number 3), residues 264 to 276.
All the antisera reacted with both the HSV-1 and HSV-2
ICP32/VP19c proteins, although antisera to peptides 1 and 2
showed some nonspecific binding to both cellular and other
viral proteins (data not shown). The results (Fig. 3B) dem-
onstrate that the peptide 2 antiserum reacts specifically with
both the HSV-1 and HSV-2 ICP32/VP19c molecules in
immunoblotting experiments. Antiserum was also prepared
from rabbits inoculated with a TrpE/HSV-2 ORF fusion
protein specifying the carboxy-terminal 197 amino acids
encoded by the ORF. The immunoblotting experiments in
Fig. 3C indicate that this antiserum directed against the
fusion protein also displayed a high affinity for both the
HSV-1 and HSV-2 ICP32/VP19c molecules. These results
strongly reinforce the conclusions of the antipeptide immu-
noblotting experiments and again demonstrate that the prod-
uct of the HSV-2 ORF must be ICP32/VP19c.
(ii) Kinetic class of ICP32/VP19c. The HSV-1 and HSV-2
ICP32 proteins have been classified as _Y2 proteins and as
such depend on viral DNA synthesis for expression (29, 81).
To ascertain the kinetic class of the HSV-1 and HSV-2
proteins reacting with the antisera, we performed immuno-
blot analyses on HSV-1 and HSV-2 ICPs produced in
infected cultures treated with PAA. Figure 4A shows SDS-
PAGE-separated 35S-labeled polypeptides (18 to 20 h post-
infection) extracted from untreated or PAA-treated, mock-
infected HSV-1-infected, or HSV-2-infected HEp-2 cells. A
comparison of the protein profiles of the untreated (lanes 1 to
3) and PAA-treated (lanes 4 to 6) infected cultures demon-
strates that PAA-mediated inhibition of viral DNA synthesis
dramatically decreased the amounts of both the HSV-1 and
HSV-2 ICP32 molecules synthesized in infected cultures.
The results of immunoblotting of the proteins produced in
untreated and PAA-treated infected cultures (Fig. 4B) dem-
onstrated that the HSV-1 and HSV-2 polypeptides that are
immunoreactive with the antipeptide sera depend on viral
DNA synthesis for expression.
Taken together, the results of these immunoblotting ex-
periments demonstrate that ICP32/VP19c is the polypeptide
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CTTTTGGCCCTGCGGCACCCCACCGACCTCCCCCACCTGGCCCGCCATCGGGCTCCGCCCGGCCGGCAGACCGAGCGACTGGCCGAGGCCTGGGGCCAGCTCCTGGAGGCCTCCGCCCTG
GGGTCCGGGCGGGCCGAGAGCGGCTGCGCGCGCGCGGGCCTTGTGTCGTTTAACTTTCTGGTGGCCGCGTGCGCCGCCGCCTACGATGCGCGCGACGCCGCCGAGGCGGTCCGGGCCCAC
GlySerGlyArgAlaGluSerGlyCysAlaArgAlaGlyLeuValSerPheAsnPhoLeuValAlaAlaCysAlaAlaAlaTyrAspAlaArgAspAlaAlaGluAlaValArgAlaHis
CGCCCTACCGCACGCACCTGCACATACGCCGCCTTCGCAGAGCTGGGTGTCATGCCAGACGACAGCCCCCGCTGTCTGCACCGCACCGAGCGGTTTGGGGCGGTCGGCGTTCCGGTTGTC
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DISCUSSION
In this report, we characterized the HSV-2 gene encoding
infected cell protein 32 (ICP32) and virion protein 19c
(VP19c). We also demonstrated that the HSV-1 UL38 and
ORF.553 ORFs, which have been shown to specify a protein
essential for capsid formation (58), must encode the cognate
HSV-1 ICP32/VP19c protein.
Comparison of ORFs encoding HSV-2 and HSV-1 1CP32/
VP19c proteins. Comparison of the HSV-1 and HSV-2 DNA
sequences encoding their respective ICP32/VP19c molecules
indicates that the overall organization of the two genes is
quite similar. However, there are a number of differences
between them. The two DNA sequences display 66% (413 of
622 nt) overall identity, with 164 mismatched and 45 un-
matched bases. Conserved features include the putative
translation start sites for the genes encoding ICP32/VP19c
and ICP10 (51), two TATA box-like structures which occur
close to the transcription initiation sites for the 3.6-kb
(ICP10) and 1.9-kb (ICP32) mRNAs previously mapped in
this region of the HSV-1 genome (58), and a conserved SP1
transcription factor-binding site (HSV-2 position 344). A
major difference is the presence in the HSV-2 sequence of
several small oligonucleotide stretches that have no counter-
parts in the HSV-1 sequence. These occur in the region
between the conserved TATA boxes that probably repre-
sents truly intergenic DNA sequences. Other dissimilarities
include the presence in the HSV-2 ICP32/VP19c ORF of a
second potential translation initiation site (ATG) and the
occurrence of possible internal transcription factor-binding
sites within the HSV-1 ORFs predicted to encode ICP32/
VP19c and ICP10 (Fig. 5).
To date, most of the studies of HSV late gene expression
have focused on the regulation of three HSV-1 Y2 genes,
US11 (39), glycoprotein C (2, 30, 31), and a gene encoding a
70-kDa regulatory protein (50, 69). These studies have
shown that Y2 gene expression depends on viral DNA
replication and can be authentically examined only in the
context of the viral genome (2, 69). Within the virus genome,
the promoter-regulatory sequences important to the expres-
sion of the glycoprotein C gene map between -34 and - 19 nt
relative to the transcription start site (30, 31). In addition,
analyses of glycoprotein C genes resident in cells have
shown that sequences downstream of +22 are needed for
-y2-specific regulation (2), suggesting that a complex array of
cis-acting elements is involved in Y2 gene regulation. The
C HSV-1 and HSV-2 DNA sequences display approximately
HSV-2-infected 76% nucleotide identity in the 5' regions of the ORFs.
fection) polypep- Nucleotide sequence variability in the promoter-regula-
infected (lane 1), tory elements of the HSV-1 and HSV-2 genes may be
electrophoresis reflected in the fact that the synthesis of the HSV-1 and
inked SDS-poly- HSV-2 proteins is affected differently by PAA. After PAA
?per (see Materi- treatment of infected cells, a small amount of HSV-1 ICP32
des produced in was detected on immunoblots with the antipeptide sera,
and HSV-2-in- while no HSV-2 ICP32 was detected under the same condi-;st the ERAGAL tions (Fig. 4). While it is possible that these viruses vary in
ted (lane 1), and their sensitivity to DNA synthesis inhibitors, studies of late
ainst the TrpE/ gene expression in other virus systems (80) suggest that the
dicates the posi- sequence variation observed in the promoter-regulatory re-
gions of the HSV-1 and HSV-2 ICP32/VP19c genes is
sufficient to generate minor differences in the levels of
g immediately expression of the two genes.
init of the viral The occurrence of a second possible translation initiation
provide strong site in the HSV-2 ICP32/VP19c ORF may account for the
F (51, 58) must observed differences in the synthesis or processing or both
of the proteins. Thus, the HSV-1 and HSV-2 ICP32/VP19c
J. VIROL.
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FIG. 4. Effect of PAA on Western immunoblots of HSV-1- and HSV-2-infected cell polypeptides. (A) Polypeptide profiles obtained after
SDS-PAGE (9.5% N,N'-diallyltartardiamide) of 35S-labeled (18 to 20 h postinfection) proteins synthesized in mock-infected (lane M),
HSV-1-infected (lane 1), and HSV-2-infected (lane 2) cultures (lanes 1 to 3) or in identically processed cultures treated with 300 ,ug of PAA
per ml throughout infection (lanes 4 to 6). (B) Western blot of polypeptides produced in untreated and PAA-treated mock-infected (lane M),
HSV-1-infected (lane 1), and HSV-2-infected (lane 2) cultures after reaction with rabbit antiserum directed against the ERA oligopeptide.
proteins differ with respect to electrophoretic mobilities
(Fig. 3 and 4) even though the HSV-1 UL38 ORF is
predicted to encode a 465-amino-acid polypeptide of 50,269
Da and the HSV-2 ORF is predicted to encode a similarly
sized 466-amino-acid polypeptide of 50,538 Da. These elec-
trophoretic differences were previously noted by Morse et
al. (56), who estimated the size of HSV-1 ICP32 at 51,500 Da
and that of HSV-2 ICP32 at 50,500 Da. A straightforward
manner of reconciling the predicted sizes of the HSV-1 and
HSV-2 ICP32 proteins with their experimentally determined
sizes would be to assume that the HSV-1 protein is more
extensively modified than the HSV-2 protein by posttrans-
lational phosphorylation or other additions. However, early
in infection, the HSV-2 protein displays an electrophoretic
mobility equivalent to that of HSV-1 ICP32, but as infection
progresses, the mobility of the HSV-2 protein appears to
increase while that of the HSV-1 protein remains constant
(data not shown). In addition, two to three radiolabeled
bands were detected in infected cell extracts after SDS-
PAGE that seem to be intermediates between the faster ana
slower forms of HSV-2 ICP32. It is important that only the
smallest of these seemingly related forms of the HSV-2
2
$ ICP32
4
PA A 0
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1 TGCAACGGTCCGTTCGGGGGTGGAGCGGACGGGGGGGTCATGCCGGCGGGCGCCGGGACC
MIii 1111111 11 III III III 11 1 1111 11 11 III III 1
84005 TGCATAGGTCCGTCCGAGGGCGGACCGGCGGGTGAGGTCGTGACGACGGGGGCCTCGGAC
SPi > < CREB/ATF
61 TGGAGCGCGCTGTCCGACATGGCGACCGGCGTGCG-CGCTCGGCGAC-GCGGCGCGGAGA
MI III I II Il II 11111 III I 11 III III I 1
84065 GGGAGACCGCGGTCTGCCATGACGCCCGGCTCGCGTGGGTGGGGGACAGCGTAGACCA-A
< Spi
109 CCGCGGGCCCAAACGGGAATGACTGCCGCCGCCCTATACGGAGGGGCTAAGTATCG---C
11 1 11 111111111111II11111111I11111111111111i 1
84124 CGACGAGACCGGGCGGGAATGACTGTCG-TGCGCTGTAGGGAGCGGCGAATTATCGATCC
Spi >
166 CCGGGGACCCTTC-GAAACCCCGGGCGTGTCGCAAGTACGCCGCGAAGGCGCGGCGTGTT
11 1111 11111 11 11 11111 11111 11111 11111
84183 CCCGCGGCCCTCCAGGACCCCCGCAGGCGTTGCGAGTACCCCGCGTCTTCGCGGGGTGTT
215
84243
275
84291
1111111 III IIIIIIIIII IIIIIII 1111111
ATACGGCCACTTAAGTCCCGGCATCCCGTTCGCGGACCCAGGCCCGG------------G
spi >
GGAGTGTGTGTGTGGGGGGGGGGCGGCGCGACGGCGGCCCGGACCAAGTGTATCGCGGCC
111111 11 1III II 11111111 III 1 1111 1
GGATTGT-------CCGGATGTGCG-------GGCAGCCCGGACGGCGTGGGTTGCGGAC
Spi >
335 GTTCCGTGGGGCGGCCCAACAGGCCCTTTAAACATTTGCGTATGCACCGGCCCAGCCAGT
III 111111111111 111111111111 I 11 11 1 11 III 111111
84337 TTTCTGCGGGGCGGCCCAAATGGCCCTTTAAACGTGTGTATACGGACGCGCCGGGCCAGT
Spi > >>>
395 CGGACACCGGAACCCACCAGAGGCGGAAGCCGCCTTCGCCCGTGAGGGTGCGTGTGTTTT
111 11 I 11111111 1111111111 1111 III 11 11 111
84397 CGGCCAACACAACCCACCGGAGGCGGTAGCCGCGTTTGGCTGTG-GGGT--GGGTGGTTC
< Spi
455 CTGGTGGCGTGTTTTTCCTTTCCGCCCTCCTCCCTCCCCACCACCACCACCCCCCACTCG
1 H1 1 11H1 11 I 11II llIllI 11 11 111 III
84454 CGCCTTGCGTGAGTGTCCTTT-CGAC--CCCCCCCCCCCTC--CCTCC-CCCGGGTCTTG
515 CCCGTTGGCGATCGGCGGGAAAACCATGAAAACCAAGCCACTCCCGACAGCCCCGATGGC
I I I HI M1 III I IIIII Hi 1 11 11 11 11 lill 1
84508 CTAGGTCGCGATC--TGGGGTCGCAATGAAGACCAATCCGCTACCCGCAACCCCTTCCGT
575
84564
GTGGGCCGAGAGTGCCGTGGAA
11111 11 1111 11111111
GTGGGGCGGGAGTACCGTGGAA
spi >
FIG. 5. Comparison of the HSV-2 DNA sequences upstream of the 1CP32/VP19c gene with the HSV-1 (strain 17) UL37-UL38 intragenic
region (51). The HSV-2 DNA sequences upstream of the gene encoding ICP32/VP19c are aligned with nt 84005 to 84585 of the HSV-1 (strain
17) DNA sequence. This region of HSV-1 DNA contains portions of the UL37 and UL38 ORFs together with intergenic DNA sequences.
Translational start sites for the HSV-1 and HSV-2 ICP32- and ICP10-encoding ORFs are indicated by the underscored and overscored ATGs
and CATs, respectively. A second possible translation start site occurring in the HSV-2 ICP32 ORF is also indicated. Transcription initiation
sites and orientation of transcripts mapped for the HSV-1 1.9-kb (ICP32) and 3.6-kb (ICP10) mRNAs (58) are denoted by triple-headed arrows.
The locations of potential transcription factor-binding sites identified by a computer search for 44 such sites are denoted by the triple-headed
arrows.
ICP32/VP19c protein has been identified as a constituent of
the capsid (8). There are a number of possible mechanisms
that could generate multiple forms of HSV-2 ICP32 at
different times postinfection. The most plausible would
appear to be a switch to an alternate site of translational
initiation late in virus infection (24). Posttranslational addi-
tions to the resultant smaller polypeptide might then give rise
to the intermediate-size bands. In support of this interpreta-
tion, the HSV-2 ICP32/VP19c ORF does contain a second
ATG codon 30 nt downstream of the first, within a Kozak
milieu (42-44), which might function as an alternate transla-
tion initiation site. The HSV-1 ICP32/VP19c ORF lacks such
a second ATG. Alternatively, the different-sized HSV-2
ICP32/VP19c proteins might arise from proteolytic process-
ing of a larger precursor into progressively smaller forms of
the protein. However, the cognate HSV-1 protein does not
appear to be subject to such processing, and computer
analysis of the predicted HSV-1 and HSV-2 proteins with
respect to known protease cleavage sites failed to reveal any
substantial differences in expected protease sensitivities
between the two molecules. Also, the predicted HSV-2
polypeptide does not contain cleavage sites for known
proteases that might generate cleavage products similar in
size to the observed HSV-2 ICP32/VP19c molecules.
The HSV-2 DNA and predicted protein sequences deter-
mined in this study were analyzed with respect to significant
J. VIROL.
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FIG. 6. (A) Comparison of the predicted amino acid sequence of the HSV-2 ICP32/VP19c protein with related gene products from other
herpesviruses. The predicted amino acid sequence of the HSV-2 ICP32/VP19c molecule is aligned with the products of the HSV-1 UL38 (51),
VZV 20 (18), and EBV BORF1 (3) ORFs. Residue assignments are given in the single-letter amino acid code. The consensus sequence
indicates positions in which all four predicted proteins display amino acid identity or conservative substitution (*). (B) Comparison of the
hydropathicity plots of the VP19c-related herpesvirus proteins. This comparative alignment of hydropathicity plots of the predicted products
of the ORFs encoding the related herpesvirus proteins is based on the results of primary sequence alignment presented in panel A.
homologies to known oncogenes or tumor suppressor pro-
tein-binding motifs because this ORF, which encodes a
DNA-binding protein, maps to a region of the viral genome
(mtr-III) implicated in cellular transformation (6, 23, 38, 68).
No significant homologies were found.
Structure and functions of ICP32/VP19c-related herpesvi-
rus proteins. Several reports have noted that the sequences
of the predicted proteins of the HSV-1 UL38/ORF.553 (51,
58), VZV 20 (18), and EBV BORFi (3) ORFs are signifi-
cantly related. Computer analysis of the predicted HSV-2
ICP32/VP19c sequence indicated that it also is a member of
this family of viral proteins (Fig. 6A). The HSV-2 protein
displays significant amino acid identity with the HSV-1
(78%, 466-amino-acid overlap), VZV (29%, 362-amino-acid
HSV- i
UL38
vzv
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overlap), and EBV (20.2%, 119-amino-acid overlap) pro-
teins. Much of the sequence variation in this group of
proteins occurs in the region equivalent to the amino-
terminal 100 to 120 amino acids of the HSV-2 ICP32 protein.
Such amino-terminal variation has been noted before in
other comparisons of related groups of herpesvirus proteins
(11, 26, 74). However, the observation that the predicted
EBV BORF1 product appears to be completely missing an
equivalent protein domain, coupled with the hypothesis that
the HSV-2 protein may exhibit alterations in this region due
to alternative translational initiation late in infection, sug-
gests that this region of the molecules is not essential for
protein function. Analysis of the primary amino acid se-
quences of this family of viral proteins failed to reveal any
obvious structural motifs that might explain the previously
reported DNA-binding properties of the HSV-1 and HSV-2
VP19c molecules (9).
Comparative hydropathicity analysis (45) (Fig. 6B) of the
ICP32/VP19c family of herpesvirus proteins illustrates two
important points. First, with respect to hydropathicity, the
HSV-1, HSV-2, and VZV proteins appear remarkably simi-
lar beyond the first 100 or so amino acids. Most of the amino
acid substitutions that have occurred among these three viral
proteins have been very conservative. The physical and
biochemical properties of these proteins might also be ex-
pected to be conserved. Second, while the EBV BORF1
protein sequence is significantly related to the other pro-
teins, it has diverged considerably with respect to size and
predicted physical properties. This variance is not untoward
given the postulated evolutionary relationships between the
alpha Herpesviridae (HSV-1, HSV-2, and VZV) and the
gamma Herpesviridae (EBV) (32). However, the extent of
variation is somewhat surprising in a gene that presumably
encodes the EBV counterpart of the essential capsid struc-
tural protein VP19c. It will be of interest to examine the
DNA sequences of the members of the related beta Herpes-
viridae to determine whether they also encode a protein
related to VP19c.
The role of the VP19c molecule in capsid structure and
virion assembly is currently unclear. The available evidence
is as follows. (i) VP19c is an integral structural part of type
A capsids (25, 66) and is essential for capsid formation (59).
(ii) It may form a disulfide bond to VP5, the major capsid
protein that makes up the hexameric capsomeres (19, 22,
83). (iii) Both HSV-1 and HSV-2 VP19cs after denaturation
and partial renaturation display affinity for DNA (8). (iv)
VP19c has been reported to be both a component of pen-
tameric capsomeres (78) and an internal virion protein (8, 9,
25). If VP19c does compose the HSV pentameric caps-
omeres, it obviously has an essential role in capsid assem-
bly, and its juxtaposition to the hexameric capsomeres might
allow for disulfide bonding to VP5. However, the DNA-
binding properties of the HSV-1 and HSV-2 VP19c mole-
cules seem difficult to reconcile with a pentamer assignment.
Also, if the predicted product of the EBV BORF1 gene has
an analogous role in the structure of the EBV capsid, then it
would appear that a rather different structural solution to
pentamer assembly must occur in the EBV capsid compared
with the HSV capsids. If, on the other hand, a significant
portion of VP19c is located in the capsid interior, then it may
contribute to the band of mass density shown by Schrag et
al. (66) to lie directly beneath the hexameric capsomeres.
VP19c might thus form part of an essential matrix holding
the hexamers together, and it might easily form disulfide
bonds to VP5 (66). In this position, VP19c might also be
oriented in such a manner as to present a DNA-binding
domain to the interior of the capsid, thus conferring a strong
affinity for DNA to the interior surface of the empty type A
capsid. Such a molecular arrangement could be important
for the processes of viral DNA packaging or virion core
formation or both. In addition, if all the VP19c-related
herpesvirus proteins function similarly, then the divergent
structure of the product of the EBV BORF1 gene, in
particular, suggests that the internal capsid structures of the
herpes family of viruses differ substantially. Such variations
in internal capsid architecture may reflect or influence the
size of the viral genomes packaged by each of the herpesvi-
ruses.
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